Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.

about

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

P2860

Q58770498-A9EA5B89-08CC-4E9C-9CB1-FD5BBA5A7971

P2860

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.

Item

http://www.wikidata.org/entity/Q54209728

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Efficacies of Cabotegravir and ...... stant HIV-1 integrase mutants.

@en

Efficacies of Cabotegravir and ...... stant HIV-1 integrase mutants.

@nl

type

Item

label

Efficacies of Cabotegravir and ...... stant HIV-1 integrase mutants.

@en

Efficacies of Cabotegravir and ...... stant HIV-1 integrase mutants.

@nl

prefLabel

Efficacies of Cabotegravir and ...... stant HIV-1 integrase mutants.

@en

Efficacies of Cabotegravir and ...... stant HIV-1 integrase mutants.

@nl

P1476

Efficacies of Cabotegravir and ...... stant HIV-1 integrase mutants.

@en

P2093

Steven J Smith

http://www.w3.org/2001/XMLSchema#string

Terrence R Burke

http://www.w3.org/2001/XMLSchema#string

Xue Zhi Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Retroviral intasome assembly and inhibition of DNA strand transfer

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome

Resistance to integrase inhibitors.

Rapid screening of HIV reverse transcriptase and integrase inhibitors.

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

P2888

s12977-018-0420-7

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12977-018-0420-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stephen H. Hughes

P577

2018-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104022468

http://www.w3.org/2001/XMLSchema#string

P698

29769116

http://www.w3.org/2001/XMLSchema#string

P932

5956922

http://www.w3.org/2001/XMLSchema#string

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.

about

P2860

P2860

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932